Top European Biotech Investors of 2019 and lessons learned

    Our friends at the leading online biotech media, Labiotech.eu, recently published the article “What 2019 Can Teach About European Biotech Investments Going Forward” including among other things a list of Top European Biotech Investors of 2019. Among the highlights emphasized are also the fact that MVA-member, Genmab, pulled off a €450M Nasdaq IPO to fund the development of its antibody drug pipeline and the fact that it appears as if the most active investors not only tended to favor early-stage biotechs, but also timed their deals well.